HMGB1 and epilepsy: Liquid biomarkers have also been investigated; for example, serum High-mobility group box 1 (HMGB1) and interleukin (IL)-1β have been related to epilepsy outcomes in the pediatric population [14], and neuron-specific enolase [15] has been used to predict the outcome.